Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Atrys logo — Prevention and precision care for people

Atrys

Prevention and precision care for people

Founded 2015 Spain Spain 245 employees Post-IPO Equity Total: $81.20M Biotechnology, Health Care

General Information

Company Name Atrys
Founded Year 2015
Location Spain Spain
Founders / Decision Makers
Team member Team member Team member
Employees 245
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Atrys. To contact Atrys, visit atryshealth.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Atrys compare?

A PDF of Atrys and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Atrys soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Atrys

Atrys is a global company that provides precision medical diagnosis and treatment services, pioneering in telemedicine and state-of-the-art radiotherapy. The company has a team of over 2,000 professionals and operates in Spain, Portugal, Switzerland, and Latin America. Atrys' main areas of business are in oncology - including high-precision medical and radiation therapy - diagnostics - encompassing genetic diagnosis, anatomical pathology, and telemedicine - and preventive medicine - focused on workplace risk prevention and health education, serving over a million workers through its network of 234 branches. Founded in 2007, the company began trading on the BME Growth in 2016 and on the main market of the Spanish stock exchange in February 2022. A recent significant development for Atrys is a €72.00M Post-IPO Equity investment received on 15 June 2022. This funding further strengthens its position in the biotechnology and healthcare sectors. Atrys' commitment to precision care and its expansion into new markets position it as an attractive prospect for venture capitalists seeking impactful investments in the healthcare industry.

Business keywords: precision medicine, oncology diagnostics, radiation oncology, telemedicine, pathological anatomy, genetic diagnostics, occupational health, BME Growth, medical treatments, diagnostic imaging, biomedical company, data analytics in healthcare, clinical oncology, radiation therapy

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €72.00M -
15 Jun 2022
Post IPO Equity Undisclosed 1
Fides Capital
Fides Capital
01 Jul 2020
Series B €9.20M 1
Banco Sabadell
Banco Sabadell
11 Jan 2018

Atrys Alternatives & Competitors

View All Alternatives
Atrys vs
广州嘉检医学检测有限公司
广州嘉检医学检测有限公司 China

使命宣言： •为我们的民众提供高品质的，临床合理的综合诊断和咨询服务，通过个性化诊断实现精准医学。...

Series B
27 employees
Biotechnology, Care Economy
Compare Atrys vs 广州嘉检医学检测有限公司
Atrys vs
ViewRay, Inc.
ViewRay, Inc. United States

Conquer cancer by re-envisioning radiation therapy.

Post-IPO Debt
76 employees
Biotechnology, Health Care
Compare Atrys vs ViewRay, Inc.
Atrys vs
Aperio
Aperio United States

For over a decade, Aperio has advanced the technology that enables glass slides to be digitized and...

Debt Financing
86 employees
Biotechnology, Health Care
Compare Atrys vs Aperio
View all alternatives

FAQ About Atrys

Prevention and precision care for people
Atrys was founded in 2015.
Atrys is headquartered in Spain.
Atrys operates in Biotechnology and Health Care. Its work centres on precision medicine, oncology diagnostics, radiation oncology and telemedicine.
Atrys has approximately 245 employees.
Atrys has completed 3 funding rounds, raising a total of $81.20M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Atrys include 广州嘉检医学检测有限公司, ViewRay, Inc., Aperio, OncoDNA, Sano Genetics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Atrys and 广州嘉检医学检测有限公司 are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Atrys, https://www.bouncewatch.com/company/atrys, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout